The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale.
The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale.
复制标题
动脉粥样硬化 (Proof-ATHERO) 联盟的前瞻性研究：设计和基本原理。
作者：
Tschiderer,Lena;Seekircher,Lisa;Klingenschmid,Gerhard;Izzo,Raffaele;Baldassarre,Damiano;Iglseder,Bernhard;Calabresi,Laura;Liu,Jing;Price,JackieF;Bae,Jang-Ho;Brouwers,FrankP;deGroot,Eric;Schmidt,Caroline;Bergström,Göran;Aşçi,
动脉粥样硬化是大多数心血管疾病共有的病理生理机制，可以通过各种临床测试直接或间接评估，包括颈动脉内膜中层厚度、颈动脉斑块、踝肱指数、脉搏波速度和冠状动脉钙的测量。动脉粥样硬化前瞻性研究 - (Proof-ATHERO) 联盟 (https://clinicalepi.i-med.ac.at/research/proof-athero/) 将研究的去识别化个体参与者数据与动脉粥样硬化测量、心血管疾病危险因素和心血管疾病发病率信息进行整理。目前，它包含 74 项研究，涉及来自 25 个国家和 40 多个城市的 106,846 名参与者。总之，21 项研究从普通人群中招募了参与者（n = 67,784），16 项研究从高危人群中招募了参与者（n = 22,677），37 项研究作为临床试验的一部分（n = 16,385）。贡献研究的基线年份范围为 1980 年 4 月至 2014 年 7 月；最近一次随访截至 2019 年 6 月。基线平均年龄为 59 岁（标准差：10），其中 50% 为女性。在总共 830,619 人年的随访中，记录了 17,270 起心血管事件（包括冠心病和中风）和 13,270 例死亡，对应的每年累积发病率分别为 2.1% 和 1.6%。该联盟由奥地利因斯布鲁克医科大学临床流行病学团队协调。贡献研究在纳入 Proof-ATHERO 中央数据库之前要经过详细的数据清理和协调程序。统计分析是根据预先定义的分析计划进行的，并使用既定的方法进行个体参与者数据荟萃分析。多机构协作 Proof-ATHERO 联盟利用其大样本量，旨在更好地表征、理解和预测动脉粥样硬化的发展及其临床后果。
Atherosclerosis–the pathophysiological mechanism shared by most cardiovascular diseases–can be directly or indirectly assessed by a variety of clinical tests including measurement of carotid intima-media thickness, carotid plaque,-ankle-brachial index, pulse wave velocity, and coronary-artery calcium. The Prospective Studies of Atherosclerosis-(Proof-ATHERO) consortium (https://clinicalepi. i-med. ac. at/research/proof-athero/) collates de-identified individual-participant data of studies with information on atherosclerosis measures, risk factors for cardiovascular disease, and incidence of cardiovascular diseases. It currently comprises 74 studies that involve 106,846 participants from 25 countries and over 40 cities. In summary, 21 studies recruited participants from the general population (n= 67,784), 16 from high-risk populations (n= 22,677), and 37 as part of clinical trials (n= 16,385). Baseline years of contributing studies range from April 1980 to July 2014; the latest follow-up was until June 2019. Mean age at baseline was 59 years (standard deviation: 10) and 50% were female. Over a total of 830,619 person-years of follow-up, 17,270 incident cardiovascular events (including coronary heart disease and stroke) and 13,270 deaths were recorded, corresponding to cumulative incidences of 2.1% and 1.6% per annum, respectively. The consortium is coordinated by the Clinical Epidemiology Team at the Medical University of Innsbruck, Austria. Contributing studies undergo a detailed data cleaning and harmonisation procedure before being incorporated in the Proof-ATHERO central database. Statistical analyses are being conducted according to pre-defined analysis plans and use established methods for individual-participant data meta-analysis. Capitalising on its large sample size, the multi-institutional collaborative Proof-ATHERO consortium aims to better characterise, understand, and predict the development of atherosclerosis and its clinical consequences.